Search Results

You are looking at 111 - 120 of 2,569 items for :

  • Refine by Access: All x
Clear All
Full access

Cari Utendorf, Amy Compston, and Brittany Knauss

intervention to prevent further functional decline throughout cancer treatment. Methods : Physical therapy (PT) is integrated in the cancer-aging resiliency and pancreatic clinics. A PT evaluation is completed, with the following outcomes obtained as listed in

Full access

Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth

-rituximab era, risk-stratified, response-based, multiagent chemotherapy included higher doses and additional cycles of chemotherapy for patients with higher-stage disease and resulted in cure rates ranging from 79% to 98% ( Table 1 ). Table 1. Outcomes for

Full access

Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong

and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma

Full access

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

lack of lymph node sampling. AREN0532 demonstrated an excellent outcome with a high salvage rate for patients with disease relapse using a standardized regimen (DD4A; doxorubicin/vincristine/dactinomycin) and radiation therapy (RT) ( Table 2 ). 8 A

Full access

Carlos H. Barcenas, Maryam N. Shafaee, Arup K. Sinha, Akshara Raghavendra, Babita Saigal, Rashmi K. Murthy, Ashley H. Woodson, and Banu Arun

primary outcome of interest was documentation of a formal recommendation from the medical provider for a genetic counseling session. Using the prospectively maintained Breast Cancer Database Management System housed in the Department of Breast Medical

Full access

Mark L. Gonzalgo and H. Ballentine Carter

The use of prostate-specific antigen (PSA) testing for prostate cancer screening has increased dramatically over the past decade. Determining the most efficient way to use PSA testing and how to interpret total PSA levels and changes in PSA values over time remain challenging. Guidelines for early detection of prostate cancer have a direct impact on the number of unnecessary tests performed and are critical for developing a successful screening approach for prostate cancer. The age at which PSA screening should begin, PSA testing intervals, and the importance of understanding fluctuations in PSA values over time are discussed in the framework of recent discoveries in the field. Results from ongoing randomized trials will confirm whether prostate cancer screening is an effective method for reducing deaths from prostate cancer and what approaches will provide the most cost-effective screening strategies.

Full access

Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative

surgeon’s ability to achieve a meticulous cancer dissection. This may impair oncologic outcomes, particularly for locally advanced lower rectal cancer in male patients. 2 – 4 A laparoscopic rectal cancer operation results in short-term patient benefits

Full access

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag, and Tanios Bekaii-Saab

Background Nodal status has long been considered a key pathologic factor in cancer management and care. Previous studies have demonstrated an association between lymph node yield and status with regard to patient outcomes in colorectal cancer

Full access

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

pathologic complete response (pCR). 11 HER2 expression was found in 27% of resected locally advanced rectal adenocarcinomas and may be associated with improved outcomes after multimodality therapy. 12 A key potential resistance mechanism in colorectal

Full access

Jill R. Tichy, Elgene Lim, and Carey K. Anders

-related survival over the past 2 decades. 2 Several factors may explain the poor outcomes observed in this population, which may include a limited understanding of the biology of these cancers, inadequate clinical trial representation, and unique psychosocial and